New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. ALISO VIEJO, Calif., February 4, 2026, — Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its…

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease  ALISO VIEJO, Calif., February 2, 2026 — Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the company’s commitment to diagnostic accuracy. A…

Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry’s Patient for LifeTM program      ALISO VIEJO, Calif. – October 20, 2025 – Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:…

The Ambry CARE Program® brings accurate, personalized breast cancer risk assessments directly into clinical workflows helping direct patients at high risk for breast cancer to seek additional screening, ALISO VIEJO, Calif., October 1, 2025 – Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) and a pioneer in clinical genomic testing,…

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ALISO VIEJO, Calif., June 25, 2025 – Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced…

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes      ALISO VIEJO, Calif., DATE, 2025 – Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of…

New data, published in Nature, advances our understanding of genetic mutations and their role in cancer development ALISO VIEJO, Calif., January 8, 2025 – Ambry Genetics, a leader in clinical genomic testing, today announced its contribution to a study published in Nature that significantly advances our understanding of BRCA2 gene variants. As the uptake of…

Aliso Viejo, CA — December 12, 2024 — Ambry Genetics is proud to announce it has earned three additional Comparably Best Place to Work Awards for 2024, including Best Company Compensation, Best CEO, and Best Company Culture. These accolades join Ambry’s earlier awards for Best Career Growth 2024 and Best Company Work-Life Balance, further cementing the…